|
US5461081A
(en)
*
|
1989-09-28 |
1995-10-24 |
Alcon Laboratories, Inc. |
Topical ophthalmic pharmaceutical vehicles
|
|
US5521222A
(en)
*
|
1989-09-28 |
1996-05-28 |
Alcon Laboratories, Inc. |
Topical ophthalmic pharmaceutical vehicles
|
|
WO1993016701A2
(en)
*
|
1992-02-21 |
1993-09-02 |
Alcon Laboratories, Inc. |
Topical antiglaucoma compositions comprising carbonic anhydrase inhibitors and beta-blockers
|
|
US5932572A
(en)
*
|
1992-02-21 |
1999-08-03 |
Alcon Laboratories, Inc. |
Topical anti-glaucoma compositions
|
|
AU3722793A
(en)
*
|
1992-09-17 |
1994-04-12 |
Alcon Laboratories, Inc. |
Topical carbonic anhydrase inhibitor composition
|
|
SE9301877D0
(sv)
*
|
1993-06-02 |
1993-06-02 |
Kabi Pharmacia Ab |
In situ gel for therapeutic use
|
|
CN1129400A
(zh)
*
|
1994-05-06 |
1996-08-21 |
阿尔康实验室公司 |
维生素e生育酚衍生物在眼科组合物中的应用
|
|
US6172054B1
(en)
|
1995-06-15 |
2001-01-09 |
Alcon Laboratories, Inc. |
Combination therapy for lowering and controlling intraocular pressure
|
|
US5696166A
(en)
*
|
1995-10-31 |
1997-12-09 |
Yanni; John M. |
Compositions containing hydroxyeicosatetraenoic acid derivatives and methods of use in treating dry eye disorders
|
|
US6441047B2
(en)
|
1995-11-17 |
2002-08-27 |
Alcon Manufacturing Ltd.. |
Combination therapy for treating glaucoma
|
|
EP1057486A1
(en)
*
|
1995-11-17 |
2000-12-06 |
Alcon Laboratories, Inc. |
Use of drug combination for treating Glaucoma
|
|
FR2754712B1
(fr)
|
1996-10-17 |
1999-09-03 |
Merck Sharp Dohme Chibret Lab |
Compositions ophtalmiques
|
|
CH690814A5
(it)
*
|
1996-11-04 |
2001-01-31 |
Applied Pharma Res |
Composizioni per uso topico contenenti polisaccaridi solfati.
|
|
ZA989513B
(en)
|
1997-10-21 |
1999-04-21 |
Alcon Lab Inc |
Compositions containing histamine H2 agonists and methods of use in treating dry eye
|
|
US6261547B1
(en)
|
1998-04-07 |
2001-07-17 |
Alcon Manufacturing, Ltd. |
Gelling ophthalmic compositions containing xanthan gum
|
|
US6174524B1
(en)
|
1999-03-26 |
2001-01-16 |
Alcon Laboratories, Inc. |
Gelling ophthalmic compositions containing xanthan gum
|
|
AU2183900A
(en)
|
1998-12-24 |
2000-07-31 |
Alcon Laboratories, Inc. |
Ep4 receptor agonists for treatment of dry eye
|
|
US6462080B1
(en)
|
1998-12-24 |
2002-10-08 |
Alcon Manufacturing, Ltd. |
Prostaglandin E receptor agonists for treatment of dry eye
|
|
ATE312103T1
(de)
|
1999-01-25 |
2005-12-15 |
Nat Jewish Med & Res Center |
Substituierte porphyrine und deren therapeutische verwendungen
|
|
PT1225898E
(pt)
|
1999-11-01 |
2003-10-31 |
Alcon Inc |
Composicoes farmaceuticas contendo um farmaco antibiotico de fluoroquinolona e goma xantana
|
|
PT1228030E
(pt)
|
1999-11-09 |
2005-08-31 |
Alcon Inc |
Derivados benzenoidicos do acido 15-hidroxieicosatetraenoico e metodos para a sua utilizacao no tratamento das perturbacoes do olho seco
|
|
DK1228027T3
(da)
|
1999-11-09 |
2004-07-19 |
Alcon Inc |
3-heteroatomsubstituerede og to carbonhomologe af 15-HETE og fremgangsmåder til anvendelse
|
|
HK1045985B
(en)
|
1999-11-09 |
2004-04-23 |
Alcon, Inc. |
15-hydroxyeicosatetraenoic acid-related compounds and methods of use
|
|
PT1228032E
(pt)
|
1999-11-09 |
2004-10-29 |
Alcon Inc |
Composicoes contendo derivados do acido hidroxieicosatetraenoico e metodos de utilizacao para o tratamento de desordens do olho seco
|
|
WO2001034550A2
(en)
|
1999-11-09 |
2001-05-17 |
Alcon Universal Ltd. |
15-hydroxyeicosatetraenoic acid analogs with enhanced metabolic stability and methods of their use in treating dry eye disorders
|
|
ATE258791T1
(de)
|
1999-11-09 |
2004-02-15 |
Alcon Inc |
Lipoxin-a4 und deren analoge zur behandlung von trockenen augen
|
|
DE60019322T2
(de)
|
1999-11-09 |
2005-09-08 |
Alcon Inc. |
Heteroatomunterbrochene analoge von15-hydroxyeicosatetraensäure und verfahren zu deren verwendung
|
|
AU1226001A
(en)
|
1999-11-09 |
2001-06-06 |
Alcon Universal Limited |
Phospholipids of hydroxyeicosatetraenoic acid-like derivatives
|
|
WO2001034553A2
(en)
|
1999-11-09 |
2001-05-17 |
Alcon Universal Ltd. |
2,2-difluoro 15-hydroxyeicosatetraenoic acid analogs and methods of use
|
|
US6803385B2
(en)
|
1999-11-09 |
2004-10-12 |
Alcon, Inc. |
Hydroxyeicosatetraenoic acid analogs and methods of their use in treating dry eye disorders
|
|
CA2386632A1
(en)
|
1999-11-09 |
2001-05-17 |
Alcon, Inc. |
Omega chain modified 15-hydroxyeicosatetraenoic acid derivatives and methods of their use for the treatment of dry eye
|
|
US6458854B2
(en)
|
1999-11-09 |
2002-10-01 |
Alcon Universal Ltd. |
Phospholipids of hydroxyeicosatetraenoic acid-like derivatives and methods of use
|
|
US6552084B2
(en)
|
1999-11-09 |
2003-04-22 |
Alcon Universal Ltd. |
Hydroxyeicosatetraenoic acid analogs and methods of their use in treating dry eye disorders
|
|
PT1228028E
(pt)
|
1999-11-09 |
2005-10-31 |
Alcon Inc |
Sais de hidroxieicosatetraeniato, composicoes e metodos para utilizacao no tratamento de perturbacoes da secura ocular
|
|
AU2603301A
(en)
|
1999-12-22 |
2001-07-03 |
Alcon Universal Limited |
6-keto prostaglandin F1alpha and analogs for treating dry eye
|
|
BR0112787B1
(pt)
|
2000-07-28 |
2013-03-05 |
|
composiÇço de soluÇço topicamente administrÁvel.
|
|
PE20020578A1
(es)
|
2000-10-10 |
2002-08-14 |
Upjohn Co |
Una composicion de antibiotico topico para el tratamiento de infecciones oculares
|
|
US7060297B2
(en)
|
2000-11-06 |
2006-06-13 |
Alcon, Inc. |
Carrageenan viscoelastics for ocular surgery
|
|
US20030060447A1
(en)
*
|
2002-04-24 |
2003-03-27 |
Mutlu Karakelle |
Non-aspirating transitional viscoelastics for use in surgery
|
|
US6872382B1
(en)
|
2001-05-21 |
2005-03-29 |
Alcon, Inc. |
Use of selective PDE IV inhibitors to treat dry eye disorders
|
|
US7112588B2
(en)
*
|
2001-05-21 |
2006-09-26 |
Alcon, Inc. |
Use of proteasome inhibitors to treat dry eye disorders
|
|
JP2004527578A
(ja)
|
2001-05-21 |
2004-09-09 |
アルコン，インコーポレイテッド |
ドライアイ障害を処置するためのＮＦ−κＢインヒビターの使用
|
|
BR0209883A
(pt)
|
2001-05-21 |
2004-06-08 |
Alcon Inc |
Uso de inibidores da proteasoma para o tratamento de distúrbios do olho seco
|
|
EP1392322A1
(en)
*
|
2001-05-21 |
2004-03-03 |
Alcon, Inc. |
Method of treating dry eye disorders
|
|
EP1439842A4
(en)
*
|
2001-06-01 |
2009-09-02 |
Nat Jewish Med & Res Center |
OXIDANT CAPTAIN FOR THE TREATMENT OF DIABETES OR FOR THE USE IN THE TRANSPLANTATION OR INDUCTION OF IMMUNOTOLERANE
|
|
US6645994B1
(en)
|
2001-06-01 |
2003-11-11 |
Alcon, Inc. |
Method of treating dry eye disorders
|
|
US6750250B1
(en)
|
2001-07-12 |
2004-06-15 |
Alcon, Inc. |
11,12-oxidoarachidonic acid derivatives and methods of their use in treating dry eye disorders
|
|
US20040214754A1
(en)
*
|
2001-10-03 |
2004-10-28 |
Ellis Edward J. |
Ophthalmic preparation containing glycomacropeptide
|
|
US20040220089A1
(en)
*
|
2001-10-03 |
2004-11-04 |
Ellis Edward J. |
Ophthalmic preparation containing glycoprotein
|
|
JP4547152B2
(ja)
*
|
2001-10-23 |
2010-09-22 |
オクラホマ メディカル リサーチ ファウンデーション |
β−セクレターゼ阻害剤および使用方法
|
|
US20060234944A1
(en)
*
|
2001-10-23 |
2006-10-19 |
Oklahoma Medical Reseach Foundation |
Beta-secretase inhibitors and methods of use
|
|
TWI329105B
(en)
|
2002-02-01 |
2010-08-21 |
Rigel Pharmaceuticals Inc |
2,4-pyrimidinediamine compounds and their uses
|
|
BR0307898A
(pt)
*
|
2002-02-22 |
2004-12-07 |
Pharmacia Corp |
Formulações de droga antibiótica oftálmica contendo um composto de ciclodextrina e cloreto de cetil piridìnio
|
|
MXPA04008171A
(es)
*
|
2002-02-22 |
2004-11-26 |
Pharmacia Corp |
Formulacion oftalmica con sistema de goma.
|
|
EP2316459B1
(en)
|
2002-07-29 |
2013-11-06 |
Rigel Pharmaceuticals, Inc. |
2,4-pyrimidinediamine compounds for use in methods of treating or preventing autoimmune diseases
|
|
US8580851B2
(en)
|
2002-08-21 |
2013-11-12 |
Sucampo Ag |
Ophthalmic solution
|
|
US20040248794A1
(en)
*
|
2002-12-20 |
2004-12-09 |
Yanni John M. |
Treatment of dry eye by restoring 15-lipoxygenase activity to ocular surface cells
|
|
ATE506953T1
(de)
|
2003-08-07 |
2011-05-15 |
Rigel Pharmaceuticals Inc |
2,4-pyrimidindiamin-verbindungen und verwendungen als antiproliferative mittel
|
|
ES2431640T3
(es)
*
|
2003-08-21 |
2013-11-27 |
Sucampo Ag |
Composición oftálmica que comprende éster isopropílico de unoprostona y un agente de viscosidad
|
|
EP1799660A2
(en)
*
|
2004-09-17 |
2007-06-27 |
Comentis, Inc. |
Amino-containing compounds which inhibit memapsin 2 beta-secretase activity and methods of use thereof
|
|
AU2005286844A1
(en)
*
|
2004-09-17 |
2006-03-30 |
Comentis, Inc |
Bicyclic compounds which inhibit beta-secretase activity and methods of use thereof
|
|
EP1831225A2
(en)
*
|
2004-11-19 |
2007-09-12 |
The Regents of the University of California |
Anti-inflammatory pyrazolopyrimidines
|
|
NZ562314A
(en)
*
|
2005-04-08 |
2010-02-26 |
Comentis Inc |
Compounds which inhibit beta-secretase activity and methods of use thereof
|
|
ES2622493T3
(es)
|
2006-02-24 |
2017-07-06 |
Rigel Pharmaceuticals, Inc. |
Composiciones y métodos para la inhibición de la ruta de JAK
|
|
TW200808375A
(en)
|
2006-05-12 |
2008-02-16 |
Otsuka Pharma Co Ltd |
Hydrogel suspension and manufacturing process thereof
|
|
EP2038272B8
(en)
|
2006-06-30 |
2013-10-23 |
Sunesis Pharmaceuticals, Inc. |
Pyridinonyl pdk1 inhibitors
|
|
ATE540041T1
(de)
|
2006-11-21 |
2012-01-15 |
Rigel Pharmaceuticals Inc |
Prodrug-salze von 2,4-pyrimidindiaminverbindungen und anwendungen davon
|
|
KR20080076667A
(ko)
*
|
2007-02-15 |
2008-08-20 |
주식회사 중외제약 |
요변성 약학 조성물
|
|
CA2691531C
(en)
|
2007-06-22 |
2016-11-01 |
Board Of Regents,The University Of Texas System |
Formation of stable submicron peptide or protein particles by thin film freezing
|
|
US20100286145A1
(en)
*
|
2007-07-26 |
2010-11-11 |
Comentis, Inc. |
Isophthalamide derivatives inhibiting beta-secretase activity
|
|
JP5055432B2
(ja)
*
|
2007-09-24 |
2012-10-24 |
コメンティス，インコーポレーテッド |
治療のためのβ−セクレターゼ阻害剤としての（３−ヒドロキシ−４−アミノブタン−２−イル）−３−（２−チアゾール−２−イル−ピロリジン−１−カルボニル）ベンズアミド誘導体及び関連する化合物
|
|
JP2011517313A
(ja)
|
2007-12-11 |
2011-06-02 |
ビアメト ファーマシューティカルズ，インク． |
金属結合部分を標的化部分と組み合わせて使用する金属酵素阻害剤
|
|
BRPI0909797A2
(pt)
*
|
2008-03-07 |
2017-08-22 |
Sun Pharma Advanced Res Co Ltd |
Composição oftálmica
|
|
CN102105146A
(zh)
|
2008-05-23 |
2011-06-22 |
国立犹太保健医院 |
用于治疗与暴露于烷化物质有关的损伤的方法
|
|
US20110224223A1
(en)
|
2008-07-08 |
2011-09-15 |
The Regents Of The University Of California, A California Corporation |
MTOR Modulators and Uses Thereof
|
|
US8618096B2
(en)
*
|
2008-07-21 |
2013-12-31 |
The Regents Of The University Of California |
Prodrug compositions and methods for using the same in treating cancer and malaria
|
|
CN104230901A
(zh)
|
2008-09-15 |
2014-12-24 |
加利福尼亚大学董事会 |
用于调节ire1、src和abl活性的方法和组合物
|
|
JP5815411B2
(ja)
|
2008-12-30 |
2015-11-17 |
ライジェル ファーマシューティカルズ， インコーポレイテッド |
ピリミジンジアミンキナーゼ阻害剤
|
|
BRPI1006942A2
(pt)
|
2009-01-23 |
2016-04-12 |
Rigel Pharmaceuticals Inc |
composto, composição farmacêutica, kit, métodos para inibir uma atividade de uma jak quinase, para tratar uma doença, para tratar a rejeição de transplante de aloenxerto em um receptor de transplante, para tratar uma reação de hipersensibilidade, e para inibir uma cascata de transdução de sinal, e, uso do composto
|
|
EP2393488B1
(en)
|
2009-02-06 |
2019-06-19 |
University Of Southern California |
Therapeutic compositions comprising monoterpenes
|
|
RU2482851C2
(ru)
*
|
2009-02-20 |
2013-05-27 |
Микро Лабс Лимитед |
Хранение стабильного продукта простагландина
|
|
CN106420756A
(zh)
|
2009-07-28 |
2017-02-22 |
里格尔药品股份有限公司 |
抑制jak途径的组合物和方法
|
|
NZ713361A
(en)
|
2009-08-17 |
2017-06-30 |
Memorial Sloan Kettering Cancer Center |
Heat shock protein binding compounds, compositions, and methods for making and using same
|
|
NZ598985A
(en)
|
2009-09-04 |
2013-07-26 |
Biogen Idec Inc |
Bruton's tyrosine kinase inhibitors
|
|
EP2485589A4
(en)
|
2009-09-04 |
2013-02-06 |
Biogen Idec Inc |
HETEROARYL-BTK INHIBITORS
|
|
IL266563B
(en)
|
2009-10-06 |
2022-09-01 |
Millennium Pharm Inc |
Heterocyclic compounds useful as pdk1 inhibitors
|
|
WO2011047384A2
(en)
|
2009-10-16 |
2011-04-21 |
The Regents Of The University Of California |
Methods of inhibiting ire1
|
|
EP2853262B1
(en)
|
2009-10-26 |
2016-11-30 |
Sephoris Pharmaceuticals, LLC |
Treatment of sunburn using analgesics and antihistamines
|
|
US20130035325A1
(en)
|
2009-11-16 |
2013-02-07 |
The Regents Of The University Of California |
Kinase inhibitors
|
|
SI2509940T1
(sl)
|
2009-12-10 |
2015-09-30 |
The Regents Of The University Of California |
Sredstva za vezavo amiloida
|
|
US8507734B2
(en)
|
2010-03-03 |
2013-08-13 |
Neonc Technologies Inc. |
Pharmaceutical compositions comprising monoterpenes
|
|
CN102918034B
(zh)
|
2010-03-30 |
2015-06-03 |
维颂公司 |
多取代芳族化合物作为凝血酶的抑制剂
|
|
AU2011242562B2
(en)
|
2010-04-24 |
2016-10-13 |
Mycovia Pharmaceuticals, Inc. |
Metalloenzyme inhibitor compounds
|
|
JP6073221B2
(ja)
|
2010-07-28 |
2017-02-01 |
ライジェル ファーマシューティカルズ， インコーポレイテッド |
Ｊａｋ経路の阻害のための組成物および方法
|
|
EP3173080B1
(en)
|
2010-08-27 |
2019-12-11 |
Neonc Technologies Inc. |
Pharmaceutical compositions comprising derivatives of perillyl alcohol
|
|
US20160038600A1
(en)
|
2012-08-03 |
2016-02-11 |
Neonc Technologies Inc. |
Pharmaceutical compositions comprising poh derivatives
|
|
US9056855B2
(en)
|
2010-10-28 |
2015-06-16 |
Viamet Pharmaceuticals, Inc. |
Metalloenzyme inhibitor compounds
|
|
WO2012058645A1
(en)
|
2010-10-29 |
2012-05-03 |
Biogen Idec Ma Inc. |
Heterocyclic tyrosine kinase inhibitors
|
|
KR101848077B1
(ko)
|
2010-11-13 |
2018-04-11 |
이노크린 파마슈티컬즈, 인크. |
금속효소 억제제 화합물
|
|
CN103328452A
(zh)
|
2010-12-13 |
2013-09-25 |
威尔金制药有限公司 |
金属酶抑制剂化合物
|
|
CN105616391B
(zh)
|
2010-12-17 |
2021-03-19 |
尼昂克技术公司 |
使用异紫苏醇的方法和装置
|
|
CN103459368B
(zh)
|
2011-02-14 |
2016-06-08 |
阿勒根公司 |
比马前列素组合物的酯衍生物和方法
|
|
CA2828360A1
(en)
|
2011-02-25 |
2012-08-30 |
The United States Of America, As Represented By The Secretary, Departmen T Of Health And Human Services |
Chrysophaentin analogs that inhibit ftsz protein
|
|
WO2012149416A2
(en)
|
2011-04-28 |
2012-11-01 |
University Of Southern California |
Human myeloid derived suppressor cell cancer markers
|
|
ES2770550T3
(es)
|
2011-05-17 |
2020-07-02 |
Univ California |
Inhibidores de quinasa
|
|
WO2012158795A1
(en)
|
2011-05-17 |
2012-11-22 |
Principia Biopharma Inc. |
Pyrazolopyrimidine derivatives as tyrosine kinase inhibitors
|
|
PL2710005T3
(pl)
|
2011-05-17 |
2017-07-31 |
Principia Biopharma Inc. |
Inhibitory kinazy tyrozynowej
|
|
EP2714069A4
(en)
|
2011-05-25 |
2015-06-24 |
Amylin Pharmaceuticals Llc |
LONG-TERM CONJUGATES WITH TWO HORMONES
|
|
AU2012273100B2
(en)
|
2011-06-19 |
2017-05-25 |
Viamet Pharmaceuticals (NC), Inc. |
Metalloenzyme inhibitor compounds
|
|
KR20140040235A
(ko)
|
2011-06-19 |
2014-04-02 |
비아멧 파마슈티컬즈, 인코포레이티드 |
금속효소 억제제 화합물
|
|
US8940735B2
(en)
|
2011-06-23 |
2015-01-27 |
Viamet Pharmaceuticals, Inc. |
Metalloenzyme inhibitor compounds
|
|
EP2726097A4
(en)
|
2011-07-01 |
2015-03-11 |
Univ California |
HERPES VIRUS VACCINE AND METHOD OF USE
|
|
CA2846496C
(en)
|
2011-09-02 |
2020-07-14 |
The Regents Of The University Of California |
Substituted pyrazolo[3,4-d]pyrimidines and uses thereof
|
|
EP2771341A4
(en)
|
2011-10-28 |
2015-09-23 |
Univ Texas |
NEW COMPOSITIONS AND METHOD FOR THE TREATMENT OF CANCER
|
|
IN2014MN01378A
(da)
|
2011-12-11 |
2015-07-03 |
Viamet Pharmaceuticals Inc |
|
|
WO2013109998A1
(en)
|
2012-01-20 |
2013-07-25 |
Viamet Pharmaceuticals, Inc. |
Metalloenzyme inhibitor compounds
|
|
CA2865504A1
(en)
|
2012-03-23 |
2013-09-26 |
Oxigene, Inc. |
Compositions and methods for inhibition of cathepsins
|
|
EP2836482B1
(en)
|
2012-04-10 |
2019-12-25 |
The Regents of The University of California |
Compositions and methods for treating cancer
|
|
WO2013173506A2
(en)
|
2012-05-16 |
2013-11-21 |
Rigel Pharmaceuticals, Inc. |
Method of treating muscular degradation
|
|
US9353087B2
(en)
|
2012-06-08 |
2016-05-31 |
Biogen Ma Inc. |
Inhibitors of Bruton's tyrosine kinase
|
|
AR091273A1
(es)
|
2012-06-08 |
2015-01-21 |
Biogen Idec Inc |
Inhibidores de pirimidinil tirosina quinasa
|
|
WO2013188452A1
(en)
|
2012-06-11 |
2013-12-19 |
The Regents Of The University Of California |
Compounds and methods of treating cancer
|
|
ES2711425T3
(es)
|
2012-08-27 |
2019-05-03 |
Allergan Inc |
Espesamiento de la córnea central reducido mediante el uso de profármacos de éster hidrófilos de beta-clorociclopentanos
|
|
US9090595B2
(en)
|
2012-08-27 |
2015-07-28 |
Allergan, Inc. |
Reduced central corneal thickening by use of hydrophilic ester prodrugs of beta-chlorocyclopentanes
|
|
SI2892900T1
(en)
|
2012-09-10 |
2018-01-31 |
Principia Biopharma Inc. |
Pyrazolopyrimidine compounds as kinase inhibitors
|
|
JP2015532287A
(ja)
|
2012-09-26 |
2015-11-09 |
ザ・リージエンツ・オブ・ザ・ユニバーシテイー・オブ・カリフオルニア |
Ｉｒｅ１の調節
|
|
CN108440571B
(zh)
|
2012-10-22 |
2022-11-04 |
希望之城 |
Etp衍生物
|
|
US9364462B2
(en)
|
2012-10-30 |
2016-06-14 |
The Regents Of The University Of California |
Alpha-1-adrenergic receptor agonist therapy
|
|
WO2014124458A1
(en)
|
2013-02-11 |
2014-08-14 |
The Regents Of The University Of California |
Compositions and methods for treating neurodegenerative diseases
|
|
US9321745B2
(en)
|
2013-03-12 |
2016-04-26 |
Allergan, Inc. |
Inhibition of neovascularization by inhibition of prostanoid IP receptors
|
|
WO2014143591A1
(en)
|
2013-03-12 |
2014-09-18 |
Allergan, Inc. |
Inhibition of neovascularization by simultaneous inhibition of prostanoid ip and ep4 receptors
|
|
EP2968296B1
(en)
|
2013-03-12 |
2020-09-02 |
The Regents of the University of California |
Gamma-secretase modulators
|
|
JP2016519662A
(ja)
|
2013-03-14 |
2016-07-07 |
ザ・リージエンツ・オブ・ザ・ユニバーシテイー・オブ・カリフオルニア |
Ｋ２ｐチャネルの調節
|
|
EP2968215B1
(en)
|
2013-03-14 |
2021-05-05 |
The Regents of the University of California |
Thiosaccharide mucolytic agents
|
|
CA2902914A1
(en)
|
2013-03-14 |
2014-09-25 |
City Of Hope |
5-bromo-indirubins
|
|
LT2968297T
(lt)
|
2013-03-15 |
2019-01-10 |
Verseon Corporation |
Multipakeistieji aromatiniai junginiai kaip serino proteazės inhibitoriai
|
|
US9227978B2
(en)
|
2013-03-15 |
2016-01-05 |
Araxes Pharma Llc |
Covalent inhibitors of Kras G12C
|
|
ES2791749T3
(es)
|
2013-03-15 |
2020-11-05 |
Verseon Corp |
Halogenopirazoles como inhibidores de la trombina
|
|
JP6806562B2
(ja)
|
2013-03-15 |
2021-01-06 |
ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア |
ｅＩＦ２α経路の調節因子
|
|
SG10201800188SA
(en)
|
2013-03-15 |
2018-02-27 |
Univ California |
Acyclic nucleoside phosphonate diesters
|
|
RU2015134772A
(ru)
|
2013-03-15 |
2017-04-21 |
Аллерган, Инк. |
Применение биматопроста для повышения выработки лептина
|
|
WO2014146111A2
(en)
|
2013-03-15 |
2014-09-18 |
The Regents Of The University Of California |
Analgesic compounds and methods of use
|
|
US8957080B2
(en)
|
2013-04-09 |
2015-02-17 |
Principia Biopharma Inc. |
Tyrosine kinase inhibitors
|
|
CA2949048A1
(en)
|
2013-05-22 |
2014-11-27 |
The Regents Of The University Of California |
Aurora kinase inhibitors
|
|
US9795691B2
(en)
|
2013-06-24 |
2017-10-24 |
City Of Hope |
Chemically-linked nanoparticles
|
|
EP3022207A4
(en)
|
2013-07-15 |
2016-12-07 |
Univ Texas |
COMPOUNDS AND METHODS FOR THE TREATMENT OF CANCER, NEUROLOGICAL ILLNESS, ETHANOL DENTURE, SCARENESS, DEPRESSION AND NEUROPATHIC PAIN
|
|
DK3035926T3
(da)
|
2013-08-19 |
2020-08-31 |
Univ California |
Forbindelser og fremgangsmåder til behandling af en epilepsilidelse
|
|
EP3035924A4
(en)
|
2013-08-20 |
2017-04-19 |
City of Hope |
Hdac8 inhibitors for treating cancer
|
|
WO2015031799A1
(en)
|
2013-08-30 |
2015-03-05 |
The Regents Of The University Of California, A California Corporation |
Scintillator nanocrystal-containing compositions and methods for their use
|
|
JO3805B1
(ar)
|
2013-10-10 |
2021-01-31 |
Araxes Pharma Llc |
مثبطات كراس جي12سي
|
|
EP3444251B1
(en)
|
2013-12-11 |
2023-06-07 |
Biogen MA Inc. |
Biaryl compounds useful for the treatment of human diseases in oncology, neurology and immunology
|
|
AU2014362231B2
(en)
|
2013-12-11 |
2019-04-04 |
Biogen Ma Inc. |
Biaryl compounds useful for the treatment of human diseases in oncology, neurology and immunology
|
|
WO2015138039A1
(en)
|
2013-12-23 |
2015-09-17 |
Memorial Sloan-Kettering Cancer Center |
Methods and reagents for radiolabeling
|
|
RS58731B1
(sr)
*
|
2014-01-22 |
2019-06-28 |
Visufarma B V |
Kompozicija koja sadrži jota-karagenan protiv virusnog konjuktivitisa
|
|
WO2015116856A2
(en)
|
2014-01-29 |
2015-08-06 |
City Of Hope |
Farnesoid x receptor antagonists
|
|
ES2919024T3
(es)
|
2014-02-11 |
2022-07-21 |
Mitokinin Inc |
Composiciones y procedimientos que utilizan las mismas para el tratamiento de enfermedades neurodegenerativas y mitocondriales
|
|
WO2015123595A1
(en)
|
2014-02-14 |
2015-08-20 |
The Regents Of The University Of California |
Cyclic peroxides as prodrugs for selective delivery of agents
|
|
JP6626831B2
(ja)
|
2014-02-20 |
2019-12-25 |
アラーガン、インコーポレイテッドＡｌｌｅｒｇａｎ，Ｉｎｃｏｒｐｏｒａｔｅｄ |
ベータ−クロロシクロペンタンの親水性エステルプロドラッグの使用による角膜中心肥厚の減少
|
|
CN112353806A
(zh)
|
2014-02-21 |
2021-02-12 |
普林斯匹亚生物制药公司 |
Btk抑制剂的盐和固体形式
|
|
US20150259288A1
(en)
|
2014-03-14 |
2015-09-17 |
City Of Hope |
5-bromo-indirubins
|
|
CN106132203B
(zh)
|
2014-03-26 |
2020-05-15 |
希望之城 |
Brca1缺陷性癌症或抗性癌症的治疗
|
|
ES2908240T3
(es)
|
2014-04-07 |
2022-04-28 |
Univ California |
Inhibidores de la enzima amida hidrolasa de ácidos grasos (FAAH) con biodisponibilidad oral mejorada y su uso como medicamentos
|
|
JP6607870B2
(ja)
|
2014-05-13 |
2019-11-20 |
メモリアル スローン ケタリング キャンサー センター |
Ｈｓｐ７０モジュレーターならびにその作製および使用方法
|
|
WO2015183794A1
(en)
|
2014-05-27 |
2015-12-03 |
City Of Hope |
Tgr5 agonist complexes for treating diabetes and cancer
|
|
WO2016004383A1
(en)
|
2014-07-03 |
2016-01-07 |
City Of Hope |
Tumor-selective ctla-4 antagonists
|
|
WO2016018917A2
(en)
|
2014-07-28 |
2016-02-04 |
The Regents Of The University Of Califoria |
Compositions and methods of making polymerized nucleic acids
|
|
US10980744B2
(en)
|
2014-08-08 |
2021-04-20 |
The Regents Of The University Of California |
High density peptide polymers
|
|
CN113620978A
(zh)
|
2014-09-11 |
2021-11-09 |
加利福尼亚大学董事会 |
mTORC1抑制剂
|
|
CN111808136B
(zh)
|
2014-09-15 |
2024-06-11 |
加利福尼亚大学董事会 |
核苷酸类似物
|
|
CN106687445A
(zh)
|
2014-09-17 |
2017-05-17 |
维颂公司 |
作为丝氨酸蛋白酶抑制剂的吡唑基取代的吡啶酮化合物
|
|
JO3556B1
(ar)
|
2014-09-18 |
2020-07-05 |
Araxes Pharma Llc |
علاجات مدمجة لمعالجة السرطان
|
|
WO2016049568A1
(en)
|
2014-09-25 |
2016-03-31 |
Araxes Pharma Llc |
Methods and compositions for inhibition of ras
|
|
JP2017528498A
(ja)
|
2014-09-25 |
2017-09-28 |
アラクセス ファーマ エルエルシー |
Ｋｒａｓ ｇ１２ｃ変異体タンパク質のインヒビター
|
|
ES2757798T3
(es)
|
2014-10-02 |
2020-04-30 |
Allergan Inc |
Profármacos de éster de gamma-lactamas y su uso
|
|
SG11201704808VA
(en)
|
2014-12-18 |
2017-07-28 |
Principia Biopharma Inc |
Treatment of pemphigus
|
|
ES2789351T3
(es)
|
2015-01-13 |
2020-10-26 |
Hope City |
Máscaras de enlace peptídico de proteínas de unión a CTLA4
|
|
UY36519A
(es)
|
2015-01-16 |
2016-08-31 |
Hope City |
Anticuerpos de penetración celular
|
|
US10227333B2
(en)
|
2015-02-11 |
2019-03-12 |
Curtana Pharmaceuticals, Inc. |
Inhibition of OLIG2 activity
|
|
KR20170131405A
(ko)
|
2015-02-12 |
2017-11-29 |
네온씨 테크놀로지스, 아이엔씨. |
페릴릴 알코올 유도체를 포함하는 의약 조성물
|
|
HUE059559T2
(hu)
|
2015-02-25 |
2022-12-28 |
Univ California |
5HT agonisták az epilepsziás rendellenességek kezelésére
|
|
MX394452B
(es)
|
2015-02-27 |
2025-03-21 |
Curtana Pharmaceuticals Inc |
Inhibicion de la actividad de olig2.
|
|
KR20170122788A
(ko)
|
2015-02-27 |
2017-11-06 |
더 리젠츠 오브 더 유니버시티 오브 캘리포니아 |
연골 재생을 가능하게 하는 소분자
|
|
RU2017131562A
(ru)
|
2015-02-27 |
2019-03-27 |
Версеон Корпорейшн |
Замещенные пиразольные соединения как ингибиторы сериновых протеаз
|
|
JP6976854B2
(ja)
|
2015-03-30 |
2021-12-08 |
シティ・オブ・ホープCity of Hope |
機械的にかみ合った複合体
|
|
ES2898765T3
(es)
|
2015-04-10 |
2022-03-08 |
Araxes Pharma Llc |
Compuestos de quinazolina sustituidos y métodos de uso de los mismos
|
|
US10428064B2
(en)
|
2015-04-15 |
2019-10-01 |
Araxes Pharma Llc |
Fused-tricyclic inhibitors of KRAS and methods of use thereof
|
|
WO2016166604A1
(en)
|
2015-04-17 |
2016-10-20 |
Ludwig Institute For Cancer Research Ltd |
Plk4 inhibitors
|
|
JP6704000B2
(ja)
|
2015-04-24 |
2020-06-03 |
ザ・リージエンツ・オブ・ザ・ユニバーシテイー・オブ・カリフオルニア |
Ｒｏｒ１−ｒｏｒ２結合のモジュレーター
|
|
EP3842448A1
(en)
|
2015-05-15 |
2021-06-30 |
City of Hope |
Chimeric antigen receptor compositions
|
|
US10787664B2
(en)
|
2015-05-26 |
2020-09-29 |
City Of Hope |
Compounds of chemically modified oligonucleotides and methods of use thereof
|
|
US10765696B2
(en)
|
2015-06-10 |
2020-09-08 |
City Of Hope |
Compositions of and methods of treatment with zwitterionic polysaccharide
|
|
US20180282310A1
(en)
|
2015-06-10 |
2018-10-04 |
Biogen Ma Inc. |
Forms and compositions of biaryl inhibitors of bruton's tyrosine kinase
|
|
WO2016210165A1
(en)
|
2015-06-24 |
2016-12-29 |
Principia Biopharma Inc. |
Tyrosine kinase inhibitors
|
|
US10758624B2
(en)
|
2015-07-02 |
2020-09-01 |
City Of Hope |
Compounds and compositions including phosphorothioated oligodeoxynucleotide, and methods of use thereof
|
|
US10144724B2
(en)
|
2015-07-22 |
2018-12-04 |
Araxes Pharma Llc |
Substituted quinazoline compounds and methods of use thereof
|
|
DK3331879T3
(da)
|
2015-08-04 |
2020-08-10 |
Rigel Pharmaceuticals Inc |
Benzazolforbindelser og fremgangsmåder til fremstilling og anvendelse af forbindelserne
|
|
EP3331543A4
(en)
|
2015-08-06 |
2019-03-20 |
City of Hope |
Cell-pollenizing protein antibody conjugates and methods of use
|
|
US11136301B2
(en)
|
2015-08-31 |
2021-10-05 |
The Regents of the University of California, A California Corporation et al. |
Broad spectrum antiviral compounds and uses thereof
|
|
EP3350181B1
(en)
|
2015-09-02 |
2023-11-01 |
The Regents of The University of California |
Her3 ligands and uses thereof
|
|
EP3350167A4
(en)
|
2015-09-04 |
2019-04-03 |
City of Hope |
Androgen receptor Antagonist
|
|
CN108348512B
(zh)
|
2015-09-17 |
2021-09-03 |
希望之城 |
Pcna抑制剂
|
|
WO2017051251A1
(en)
|
2015-09-25 |
2017-03-30 |
Ludwig Institute For Cancer Research Ltd |
3-hydroxy-quinazoline-2,4-dione derivatives and their use as nuclease modulators
|
|
WO2017058902A1
(en)
|
2015-09-28 |
2017-04-06 |
Araxes Pharma Llc |
Inhibitors of kras g12c mutant proteins
|
|
EP3356359B1
(en)
|
2015-09-28 |
2021-10-20 |
Araxes Pharma LLC |
Inhibitors of kras g12c mutant proteins
|
|
EP3356351A1
(en)
|
2015-09-28 |
2018-08-08 |
Araxes Pharma LLC |
Inhibitors of kras g12c mutant proteins
|
|
EP3356349A1
(en)
|
2015-09-28 |
2018-08-08 |
Araxes Pharma LLC |
Inhibitors of kras g12c mutant proteins
|
|
EP3356347A1
(en)
|
2015-09-28 |
2018-08-08 |
Araxes Pharma LLC |
Inhibitors of kras g12c mutant proteins
|
|
WO2017058805A1
(en)
|
2015-09-28 |
2017-04-06 |
Araxes Pharma Llc |
Inhibitors of kras g12c mutant proteins
|
|
WO2017058728A1
(en)
|
2015-09-28 |
2017-04-06 |
Araxes Pharma Llc |
Inhibitors of kras g12c mutant proteins
|
|
CN108367021A
(zh)
|
2015-10-15 |
2018-08-03 |
希望之城 |
包含硫代磷酸化寡脱氧核苷酸的化合物和组合物及其使用方法
|
|
EP3364976B1
(en)
|
2015-10-19 |
2026-03-18 |
Board of Regents, The University of Texas System |
Piperazinyl norbenzomorphan compounds and methods for using the same
|
|
WO2017070256A2
(en)
|
2015-10-19 |
2017-04-27 |
Araxes Pharma Llc |
Method for screening inhibitors of ras
|
|
AU2016342352B2
(en)
|
2015-10-23 |
2022-06-02 |
Sunesis Pharmaceuticals, Inc. |
Heterocyclic PDK1 inhibitors for use to treat cancer
|
|
JP7034078B2
(ja)
|
2015-10-23 |
2022-03-11 |
イーアールエックス ファーマシューティカルズ インコーポレイテッド |
セラストロールの類似体
|
|
US11058700B2
(en)
|
2015-10-28 |
2021-07-13 |
City Of Hope |
Macrocyclic lactones and uses thereof as modulators of purinergic receptors
|
|
KR20180081596A
(ko)
|
2015-11-16 |
2018-07-16 |
아락세스 파마 엘엘씨 |
치환된 헤테로사이클릭 그룹을 포함하는 2-치환된 퀴나졸린 화합물 및 이의 사용 방법
|
|
US9988357B2
(en)
|
2015-12-09 |
2018-06-05 |
Araxes Pharma Llc |
Methods for preparation of quinazoline derivatives
|
|
CN108603037B
(zh)
|
2015-12-10 |
2020-11-17 |
希望之城 |
细胞穿透花青偶联抗体
|
|
MX383072B
(es)
|
2015-12-24 |
2025-03-13 |
Univ California |
Reguladores del cftr y métodos para su uso
|
|
ES2913051T3
(es)
|
2015-12-24 |
2022-05-31 |
Univ California |
Reguladores de CFTR y métodos de uso de los mismos
|
|
EA038421B1
(ru)
|
2015-12-30 |
2021-08-26 |
ВиПиЭс-3, ИНК. |
Соединения, ингибирующие металлоферменты
|
|
CA3010445A1
(en)
|
2016-01-05 |
2017-07-13 |
The Regents Of The University Of California |
Benzothiazole amphiphiles
|
|
US10519442B2
(en)
|
2016-02-11 |
2019-12-31 |
City Of Hope |
Twist signaling inhibitor compositions and methods of using the same
|
|
US11208411B2
(en)
|
2016-03-17 |
2021-12-28 |
The Regents Of The University Of California |
Compositions and methods for treating parasitic diseases
|
|
WO2017172979A1
(en)
|
2016-03-30 |
2017-10-05 |
Araxes Pharma Llc |
Substituted quinazoline compounds and methods of use
|
|
PL3458448T3
(pl)
|
2016-04-25 |
2021-12-06 |
Forma Therapeutics, Inc. |
Inhibitory fasn do zastosowania w leczeniu niealkoholowego stłuszczeniowego zapalenia wątroby
|
|
CA3022432A1
(en)
|
2016-04-29 |
2017-11-02 |
Board Of Regents, The University Of Texas System |
Sigma receptor binders
|
|
TW201808914A
(zh)
|
2016-05-05 |
2018-03-16 |
嘉來克生命科學有限責任公司 |
整合應激途徑之調節劑
|
|
TWI763668B
(zh)
|
2016-05-05 |
2022-05-11 |
美商嘉來克生命科學有限責任公司 |
整合應激途徑之調節劑
|
|
CR20180560A
(es)
|
2016-05-12 |
2019-01-25 |
Anacor Pharmaceuticals Inc |
Ésteres de oxaboral y sus usos
|
|
CA3063834C
(en)
|
2016-05-26 |
2025-05-06 |
The Regents Of The University Of California |
ESTROGEN RECEPTOR MODULATOR ASSOCIATIONS
|
|
EP3475263B1
(en)
|
2016-06-27 |
2022-12-28 |
Rigel Pharmaceuticals, Inc. |
2,4-diamino-pyrimidine compounds and their use as irak4 inhibitors
|
|
CN115054586B
(zh)
|
2016-06-29 |
2024-08-02 |
普林斯匹亚生物制药公司 |
改性的释放制剂
|
|
US11045493B2
(en)
|
2016-07-11 |
2021-06-29 |
The Regents Of The University Of California |
Synthetic melanin nanoparticles and uses thereof
|
|
US10646488B2
(en)
|
2016-07-13 |
2020-05-12 |
Araxes Pharma Llc |
Conjugates of cereblon binding compounds and G12C mutant KRAS, HRAS or NRAS protein modulating compounds and methods of use thereof
|
|
JP7214632B2
(ja)
|
2016-07-21 |
2023-01-30 |
バイオジェン エムエー インク． |
ブルトン型チロシンキナーゼ阻害剤のコハク酸塩形態および組成物
|
|
AU2017302635B2
(en)
|
2016-07-29 |
2021-09-16 |
Rapt Therapeutics, Inc. |
Chemokine receptor modulators and uses thereof
|
|
US11254667B2
(en)
|
2016-08-17 |
2022-02-22 |
Children's Hospital Medical Center |
Substituted imidazo[1,2-A]pyridines as IRAK 1/4 and flt3 inhibitors
|
|
US11542261B2
(en)
|
2016-08-17 |
2023-01-03 |
Children's Hospital Medical Center |
Substituted Imidazo[1,2-a]-pyridines as IRAK 1/4 and FLT3 inhibitors
|
|
WO2018039612A1
(en)
|
2016-08-26 |
2018-03-01 |
The Regents Of The University Of California |
Compositions and methods for promoting hair growth with mpc1 inhibitors
|
|
WO2018053035A1
(en)
|
2016-09-13 |
2018-03-22 |
The Jackson Laboratory |
Targeted dna demethylation and methylation
|
|
CN109952104B
(zh)
|
2016-09-15 |
2023-03-28 |
希望之城 |
二硫etp衍生物
|
|
US10849955B2
(en)
|
2016-09-28 |
2020-12-01 |
City Of Hope |
Methods of treating pancreatic cancer using GPCR antagonists
|
|
WO2018064510A1
(en)
|
2016-09-29 |
2018-04-05 |
Araxes Pharma Llc |
Inhibitors of kras g12c mutant proteins
|
|
EP3523289A1
(en)
|
2016-10-07 |
2019-08-14 |
Araxes Pharma LLC |
Heterocyclic compounds as inhibitors of ras and methods of use thereof
|
|
ES2946001T3
(es)
|
2016-10-26 |
2023-07-11 |
Rigel Pharmaceuticals Inc |
Compuestos de pirazol amida como inhibidores de IRAK
|
|
JP7170634B2
(ja)
|
2016-10-26 |
2022-11-14 |
ライジェル ファーマシューティカルズ， インコーポレイテッド |
Ｉｒａｋ阻害剤としての使用のためのオキサゾール誘導体およびその調製のための方法
|
|
US10646540B2
(en)
|
2016-11-18 |
2020-05-12 |
City Of Hope |
Peptide inhibitors of twist
|
|
DK3547836T3
(da)
|
2016-11-30 |
2024-11-18 |
Univ Southern California |
Perillylalkohol-3 brompyruvat-konjugat og fremgangsmåder til behandling af cancer
|
|
KR20190095355A
(ko)
|
2016-12-15 |
2019-08-14 |
더 리젠츠 오브 더 유니버시티 오브 캘리포니아 |
암의 치료를 위한 조성물 및 방법
|
|
EP3562306B1
(en)
|
2016-12-29 |
2025-02-26 |
Ji Xing Pharmaceuticals Hong Kong Limited |
Metalloenzyme inhibitor compounds
|
|
JP7227157B2
(ja)
|
2016-12-29 |
2023-02-21 |
フェーズバイオ ファーマシューティカルズ，インコーポレイテッド |
金属酵素阻害剤化合物
|
|
JP7327802B2
(ja)
|
2017-01-26 |
2023-08-16 |
アラクセス ファーマ エルエルシー |
縮合ヘテロ－ヘテロ二環式化合物およびその使用方法
|
|
WO2018140513A1
(en)
|
2017-01-26 |
2018-08-02 |
Araxes Pharma Llc |
1-(3-(6-(3-hydroxynaphthalen-1-yl)benzofuran-2-yl)azetidin-1yl)prop-2-en-1-one derivatives and similar compounds as kras g12c modulators for treating cancer
|
|
EP3573954A1
(en)
|
2017-01-26 |
2019-12-04 |
Araxes Pharma LLC |
Fused bicyclic benzoheteroaromatic compounds and methods of use thereof
|
|
WO2018140599A1
(en)
|
2017-01-26 |
2018-08-02 |
Araxes Pharma Llc |
Benzothiophene and benzothiazole compounds and methods of use thereof
|
|
US11136308B2
(en)
|
2017-01-26 |
2021-10-05 |
Araxes Pharma Llc |
Substituted quinazoline and quinazolinone compounds and methods of use thereof
|
|
WO2018218069A1
(en)
|
2017-05-25 |
2018-11-29 |
Araxes Pharma Llc |
Quinazoline derivatives as modulators of mutant kras, hras or nras
|
|
US10745385B2
(en)
|
2017-05-25 |
2020-08-18 |
Araxes Pharma Llc |
Covalent inhibitors of KRAS
|
|
CN110869357A
(zh)
|
2017-05-25 |
2020-03-06 |
亚瑞克西斯制药公司 |
化合物及其用于治疗癌症的使用方法
|
|
AU2018290225A1
(en)
|
2017-06-21 |
2020-01-23 |
Mitokinin, Inc. |
Compositions and methods using the same for treatment of neurodegenerative and mitochondrial disease
|
|
CA3068305A1
(en)
|
2017-06-29 |
2019-01-03 |
Rigel Pharmaceuticals, Inc. |
Kinase inhibitors and methods for making and using
|
|
US11554178B2
(en)
|
2017-06-30 |
2023-01-17 |
City Of Hope |
Compositions and methods of modulating macrophage activity
|
|
US11389460B2
(en)
|
2017-09-15 |
2022-07-19 |
City Of Hope |
Methods and compositions for treating endometrial cancer
|
|
WO2019067015A1
(en)
|
2017-09-29 |
2019-04-04 |
City Of Hope |
RECEPTORS OF CHIMERIC ANTIGENS AND BISPECIFIC ANTIBODIES FOR THE TREATMENT OF COAT CELL LYMPHOMA
|
|
CN111386283A
(zh)
|
2017-09-29 |
2020-07-07 |
基因泰克公司 |
肽抗菌复合物及其使用方法
|
|
WO2019070917A1
(en)
|
2017-10-03 |
2019-04-11 |
The Schepens Eye Research Institute, Inc. |
COMPOUNDS AND COMPOSITIONS FOR INHIBITING THE DEGENERATION OF RETINAL PIGMENT EPITHELIUM AND METHODS USING SAME
|
|
RU2020115154A
(ru)
|
2017-10-10 |
2021-11-15 |
Сирос Фармасьютикалз, Инк. |
Производные пирролотриазина и способы ингибирования киназ там
|
|
US11618780B2
(en)
|
2017-10-20 |
2023-04-04 |
City Of Hope |
Composition and method for activating latent human immunodeficiency virus (HIV)
|
|
UY37957A
(es)
|
2017-11-02 |
2019-05-31 |
Abbvie Inc |
Moduladores de la vía de estrés integrada
|
|
CA3080804A1
(en)
|
2017-11-02 |
2019-05-09 |
Calico Life Sciences Llc |
Modulators of the integrated stress pathway
|
|
US11939320B2
(en)
|
2017-11-02 |
2024-03-26 |
Abbvie Inc. |
Modulators of the integrated stress pathway
|
|
SG11202004009TA
(en)
|
2017-11-02 |
2020-05-28 |
Calico Life Sciences Llc |
Modulators of the integrated stress pathway
|
|
UY37956A
(es)
|
2017-11-02 |
2019-05-31 |
Abbvie Inc |
Moduladores de la vía de estrés integrada
|
|
UY37958A
(es)
|
2017-11-02 |
2019-05-31 |
Abbvie Inc |
Moduladores de la vía de estrés integrada
|
|
EP3704125B1
(en)
|
2017-11-02 |
2026-03-11 |
Calico Life Sciences LLC |
Modulators of the integrated stress pathway
|
|
EP3704098B1
(en)
|
2017-11-02 |
2024-01-24 |
Calico Life Sciences LLC |
Modulators of the integrated stress pathway
|
|
EP3704096B1
(en)
|
2017-11-02 |
2026-04-22 |
Calico Life Sciences LLC |
Modulators of the integrated stress pathway
|
|
EP3706750A1
(en)
|
2017-11-06 |
2020-09-16 |
RAPT Therapeutics, Inc. |
Chemokine receptor modulators for treatment of epstein barr virus positive cancer
|
|
EP3720560A4
(en)
|
2017-12-06 |
2022-01-05 |
Ludwig Institute for Cancer Research Ltd |
METHOD OF TREATMENT OF CANCER WITH PLK4 INHIBITORS
|
|
US20210292410A1
(en)
|
2017-12-07 |
2021-09-23 |
Morphosys Ag |
Treatment paradigm for an anti-cd19 antibody and venetoclax combination treatment
|
|
IL275121B2
(en)
|
2017-12-07 |
2025-11-01 |
Amplyx Pharmaceuticals Inc |
Heterocycle substituted pyridine derivative antifungal agents
|
|
SG11202005237SA
(en)
|
2017-12-15 |
2020-07-29 |
Pyramid Biosciences Inc |
5-(2-(2,5-difluorophenyl)pyrrolidin-1 -yl)-3-(1h-pyrazol-1-yl)pyrazolo[1,5-a]pyrimidine derivatives and related compounds as trk kinase inhibitors for treating cancer
|
|
WO2019126037A1
(en)
|
2017-12-19 |
2019-06-27 |
City Of Hope |
Modified tracrrnas grnas, and uses thereof
|
|
US11918592B2
(en)
|
2018-01-16 |
2024-03-05 |
Syros Pharmaceuticals, Inc. |
Inhibitors of cyclin dependent kinase 7 (CDK7)
|
|
AU2019209470A1
(en)
|
2018-01-16 |
2020-08-13 |
Syros Pharmaceuticals, Inc. |
Inhibitors of cyclin-dependent kinase 7 (CDK7)
|
|
DK3743418T3
(da)
|
2018-01-26 |
2024-09-09 |
Rapt Therapeutics Inc |
Chemokinreceptormodulatorer og anvendelser deraf
|
|
DK3749291T3
(da)
|
2018-02-08 |
2024-04-08 |
Univ Southern California |
Fremgangsmåder til permeabilisering af blod-hjerne-barrieren
|
|
EP3765459A1
(en)
|
2018-03-13 |
2021-01-20 |
Shire Human Genetic Therapies, Inc. |
Substituted imidazopyridines as inhibitors of plasma kallikrein and uses thereof
|
|
EP4643950A3
(en)
|
2018-04-27 |
2026-01-14 |
Spruce Biosciences, Inc. |
Methods for treating testicular and ovarian adrenal rest tumors
|
|
IL312291A
(en)
|
2018-05-01 |
2024-06-01 |
Revolution Medicines Inc |
C-26-linked rapamycin analogs as MTOR inhibitors
|
|
MX2020011565A
(es)
|
2018-05-01 |
2021-01-29 |
Revolution Medicines Inc |
Analogos de rapamicina ligados a c40, c28 y c-32 como inhibidores de mtor.
|
|
HRP20231381T1
(hr)
|
2018-05-03 |
2024-03-01 |
Rigel Pharmaceuticals, Inc. |
Spojevi inhibitori rip1 i postupci za njihovo dobivanje i upotrebu
|
|
MD3788045T2
(ro)
|
2018-05-03 |
2023-09-30 |
Rigel Pharmaceuticals Inc |
Compuși inhibitori ai RIP1 și procedee de obţinere și utilizare a acestora
|
|
WO2019213611A1
(en)
|
2018-05-04 |
2019-11-07 |
Cirius Therapeutics, Inc. |
Thiazolidinedione analogs for the treatment of nafld and metabolic diseases
|
|
EP3802544A1
(en)
|
2018-06-05 |
2021-04-14 |
RAPT Therapeutics, Inc. |
Pyrazolo-pyrimidin-amino-cycloalkyl compounds and their therapeutic uses
|
|
US20220133747A1
(en)
|
2018-06-06 |
2022-05-05 |
The Regents Of The University Of California |
Estrogen receptor inhibitors and uses therof
|
|
BR112020026086A2
(pt)
|
2018-06-21 |
2021-03-23 |
Calico Life Sciences Llc |
inibidores da proteína tirosina fosfatase e métodos de uso destes
|
|
KR20210023984A
(ko)
|
2018-06-25 |
2021-03-04 |
앰플릭스 파마슈티컬스, 인크. |
헤테로환형 고리 및 아미노기로 치환된 피리딘 유도체
|
|
MX2021000887A
(es)
|
2018-08-01 |
2021-03-31 |
Araxes Pharma Llc |
Compuestos espiroheterociclicos y metodos de uso de los mismos para el tratamiento de cancer.
|
|
US20210221864A1
(en)
|
2018-08-24 |
2021-07-22 |
City Of Hope |
Masked cytokine conjugates
|
|
WO2020047510A1
(en)
|
2018-08-31 |
2020-03-05 |
Amplyx Pharmaceuticals, Inc. |
Compounds and methods for treating fungal infections
|
|
CN112955187A
(zh)
|
2018-09-10 |
2021-06-11 |
加利福尼亚大学董事会 |
二硫醇糖粘液溶解剂和其用途
|
|
TWI877863B
(zh)
|
2018-10-11 |
2025-03-21 |
美商嘉來克生命科學有限責任公司 |
整合應激路徑之前藥調節劑
|
|
WO2020092845A1
(en)
|
2018-11-01 |
2020-05-07 |
Rigel Pharmaceuticals, Inc. |
Method and composition embodiments for treating acute myeloid leukemia
|
|
CN113396150B
(zh)
|
2018-11-01 |
2024-03-12 |
凌科药业(杭州)有限公司 |
三环janus激酶1抑制剂及其组合物和方法
|
|
WO2020118683A1
(en)
|
2018-12-14 |
2020-06-18 |
Lynk Pharmaceuticals Co. Ltd. |
Benzamides of pyrazolyl-amino-pyrimidinyl derivatives, and compositions and methods thereof
|
|
JP2022516969A
(ja)
|
2019-01-08 |
2022-03-03 |
フェーズバイオ ファーマシューティカルズ，インコーポレイテッド |
金属酵素阻害剤化合物
|
|
IL286373B2
(en)
|
2019-03-14 |
2026-03-01 |
Calico Life Sciences Llc |
Protein tyrosine phosphate inhibitor compounds and uses thereof
|
|
MX2021013197A
(es)
|
2019-04-30 |
2022-02-24 |
Calico Life Sciences Llc |
Cicloalquilos sustituidos como moduladores de la vía integrada del estrés.
|
|
EP3968979A4
(en)
|
2019-05-15 |
2023-03-01 |
Bexson Biomedical, Inc. |
KETAMINE FORMULATION FOR SUBCUTANEOUS INJECTION
|
|
WO2020243612A1
(en)
|
2019-05-29 |
2020-12-03 |
Rigel Pharmaceuticals, Inc. |
Method of preventing and treating thrombosis
|
|
EP4516300A3
(en)
|
2019-06-14 |
2025-08-06 |
Children's Hospital Medical Center |
Rational therapeutic targeting of oncogenic immune signaling states in myeloid malignancies via the ubiquitin conjugating enzyme ube2n
|
|
MX2022001596A
(es)
|
2019-08-08 |
2022-03-11 |
Rigel Pharmaceuticals Inc |
Compuestos y metodos para tratar sindrome de liberacion de citocinas.
|
|
EP4013420B1
(en)
|
2019-08-14 |
2023-11-01 |
Rigel Pharmaceuticals, Inc. |
Method of blocking or ameliorating cytokine release syndrome
|
|
PE20220970A1
(es)
|
2019-08-30 |
2022-06-10 |
Rigel Pharmaceuticals Inc |
Compuestos de pirazol, formulaciones de los mismos y un metodo para usar los compuestos y/o formulaciones
|
|
CA3149926A1
(en)
|
2019-09-06 |
2021-03-11 |
Yan Chen |
Rip1 inhibitory compounds and methods for making and using the same
|
|
JP7493586B2
(ja)
|
2019-09-06 |
2024-05-31 |
ライジェル ファーマシューティカルズ， インコーポレイテッド |
Ｒｉｐ１阻害化合物ならびにそれを作製および使用するための方法
|
|
WO2021053556A1
(en)
|
2019-09-18 |
2021-03-25 |
Novartis Ag |
Nkg2d fusion proteins and uses thereof
|
|
EP4031245A1
(en)
|
2019-09-18 |
2022-07-27 |
Takeda Pharmaceutical Company Limited |
Heteroaryl plasma kallikrein inhibitors
|
|
DK4031547T3
(da)
|
2019-09-18 |
2024-09-09 |
Takeda Pharmaceuticals Co |
Plasmakallikreininhibitorer og anvendelser deraf
|
|
US12516145B2
(en)
|
2019-09-30 |
2026-01-06 |
Northwestern University |
Bioactive peptide brush polymers via photoinduced reversible-deactivation radical polymerization
|
|
US20210106584A1
(en)
|
2019-10-14 |
2021-04-15 |
Principia Biopharma Inc. |
Methods for treating immune thrombocytopenia by administering (r)-2-[3-[4-amino-3-(2-fluoro-4-phenoxy-phenyl)pyrazolo[3,4-d]pyrimidin-1-yl]piperidine-1-carbonyl]-4-methyl-4-[4-(oxetan-3-yl)piperazin-1-yl]pent-2-enenitrile
|
|
WO2021087076A1
(en)
|
2019-10-30 |
2021-05-06 |
Northwestern University |
Selenium-containing analogues of pheomelanin and related materials and methods of making
|
|
SI4055021T1
(sl)
|
2019-11-07 |
2026-02-27 |
Rigel Pharmaceuticals, Inc. |
Heterociklične spojine, ki inhibirajo rip1
|
|
EP4058456A1
(en)
|
2019-11-13 |
2022-09-21 |
RAPT Therapeutics, Inc. |
Crystalline forms of c-c chemokine receptor type 4 antagonist and uses thereof
|
|
CA3162069A1
(en)
|
2019-12-18 |
2021-06-24 |
Elliot P. Farney |
Protein tyrosine phosphatase inhibitors and methods of use thereof
|
|
US11814390B2
(en)
|
2020-01-22 |
2023-11-14 |
Principia Biopharma Inc. |
Crystalline forms of 2-[3-[4-amino-3-(2-fluoro-4-phenoxy-phenyl)-1H-pyrazolo[3,4-D]pyrimidin-1-yl]piperidine-1-carbonyl]-4-methyl-4-[4-(oxetan-3-yl)piperazin-1-yl]pent-2-enenitrile
|
|
IL296921A
(en)
|
2020-04-15 |
2022-12-01 |
Pyramid Biosciences Inc |
Methods for making receptor tyrosine kinase inhibitors
|
|
US12240813B2
(en)
|
2020-05-19 |
2025-03-04 |
Cybin Irl Limited |
Deuterated tryptamine derivatives and methods of use
|
|
GB202008919D0
(en)
*
|
2020-06-11 |
2020-07-29 |
Univ Birmingham |
Polysaccharide conpositions and therapeutic gels
|
|
AU2021328671A1
(en)
|
2020-08-18 |
2023-02-16 |
Cybin Irl Limited |
Phenethylamine derivatives, compositions, and methods of use
|
|
JP2023545015A
(ja)
|
2020-10-02 |
2023-10-26 |
ミトキニン インコーポレイテッド |
腎疾患及び線維症を治療する組成物及び方法
|
|
WO2022094409A1
(en)
|
2020-11-02 |
2022-05-05 |
Trethera Corporation |
Crystalline forms of a deoxycytidine kinase inhibitor and uses thereof
|
|
JP2023551145A
(ja)
|
2020-11-18 |
2023-12-07 |
ベクソン バイオメディカル，インク． |
医薬化合物の錯化剤塩製剤
|
|
US20240058344A1
(en)
|
2020-12-18 |
2024-02-22 |
Cornell University |
Methods of treating neurodegenerative disorders and stat3-linked cancers using suppressors of electron leak
|
|
US12357623B2
(en)
|
2021-03-03 |
2025-07-15 |
Rigel Pharmaceuticals, Inc. |
Method for treating a disease or condition using a pyrazole compound or formulation thereof
|
|
AR125587A1
(es)
|
2021-03-11 |
2023-08-02 |
Rigel Pharmaceuticals Inc |
Inhibidores heterocíclicos de la quinasa de rip1
|
|
US11918582B2
(en)
|
2021-03-15 |
2024-03-05 |
Rapt Therapeutics, Inc. |
Pyrazole pyrimidine compounds and uses thereof
|
|
CN117396474A
(zh)
|
2021-03-17 |
2024-01-12 |
武田药品工业株式会社 |
血浆激肽释放酶抑制剂
|
|
JP2024512497A
(ja)
|
2021-03-17 |
2024-03-19 |
武田薬品工業株式会社 |
血漿カリクレインの阻害剤
|
|
US20240199613A1
(en)
|
2021-03-17 |
2024-06-20 |
Takeda Pharmaceutical Company Limited |
Polycyclic inhibitors of plasma kallikrein
|
|
BR112023018619A2
(pt)
|
2021-03-17 |
2023-11-28 |
Takeda Pharmaceuticals Co |
Inibidores de heteroaril de calicreína plasmática
|
|
CN117396473A
(zh)
|
2021-03-17 |
2024-01-12 |
武田药品工业株式会社 |
血浆激肽释放酶的咪唑并吡啶基抑制剂
|
|
AU2022258467A1
(en)
|
2021-04-13 |
2023-11-30 |
Contineum Therapeutics, Inc. |
Crystalline compound of muscarinic acetylcholine m1 receptor antagonists
|
|
EP4479373A1
(en)
|
2022-02-15 |
2024-12-25 |
Cybin IRL Limited |
Therapeutic phenethylamine compositions and methods of use
|
|
WO2023156453A1
(en)
|
2022-02-15 |
2023-08-24 |
Cybin Irl Limited |
Phenethylamine derivatives, compositions, and methods of use
|
|
IL315677A
(en)
|
2022-03-23 |
2024-11-01 |
Rigel Pharmaceuticals Inc |
Pyrimid-2-yl-pyrazole compounds as irak inhibitors
|
|
WO2023192479A1
(en)
|
2022-03-31 |
2023-10-05 |
Rigel Pharmaceuticals, Inc. |
Tricyclic irak inhibitors
|
|
US12240837B2
(en)
|
2022-04-06 |
2025-03-04 |
Rapt Therapeutics, Inc. |
Chemokine receptor modulators and uses thereof
|
|
CN114504550B
(zh)
*
|
2022-04-18 |
2022-08-19 |
中山大学中山眼科中心 |
一种包含甲硝唑的眼用凝胶及其制备方法
|
|
CA3256390A1
(en)
|
2022-05-25 |
2023-11-30 |
Revolution Medicines, Inc. |
CANCER TREATMENT METHODS USING AN MTOR INHIBITOR
|
|
US12377036B2
(en)
|
2022-06-21 |
2025-08-05 |
Northwestern University |
Melanin hair dye with thickeners
|
|
TW202517627A
(zh)
|
2023-07-12 |
2025-05-01 |
美商瑞佩特治療公司 |
Ｃ－ｃ趨化因子受體４型拮抗劑的結晶型及其用途
|
|
WO2025015189A1
(en)
|
2023-07-13 |
2025-01-16 |
Comanche Biopharma Corp. |
Formulations of nucleic acid compounds and uses thereof
|
|
WO2025027529A1
(en)
|
2023-07-31 |
2025-02-06 |
Advesya |
Anti-il-1rap antibody drug conjugates and methods of use thereof
|
|
WO2025068803A1
(en)
|
2023-09-26 |
2025-04-03 |
Astrazeneca Ab |
Therapeutic combinations comprising anti-steap2 chimeric antigen receptor t cells
|
|
TW202530255A
(zh)
|
2023-12-15 |
2025-08-01 |
法商亞維西亞有限公司 |
抗ｉｌ－１ｒａｐ結合結構域及其抗體－藥物偶聯物
|
|
EP4623919A1
(en)
|
2024-03-28 |
2025-10-01 |
Marinomed Biotech AG |
Composition comprising iota-carrageenan for the treatment of dry eyes, non-viral conjunctivitis and allergic ocular conditions
|
|
WO2026022243A1
(en)
|
2024-07-23 |
2026-01-29 |
The Trustees Of The University Of Pennsylvania |
Combination of a gsk-3 inhibitor and a lsd-1 inhibitor for use in the treatment of cancer
|